"Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF V600E" by Zeus A. Antonello

Article

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF V600E

Oncotarget (2017)

Zeus A. Antonello, Harvard University
Nancy Hsu, Beth Israel Deaconess Medical Center
Manoj Bhasin, Beth Israel Deaconess Medical Center
Giovanni Roti
Mukta Joshi
Paul Van Hummelen, Harvard University
Emily Ye
Agnes S. Lo, Boston University
S. Ananth Karumanchi, Beth Israel Deaconess Medical Center
Christine R. Bryke, Quest Diagnostics
Carmelo Nucera, Beth Israel Deaconess Medical Center

Link

Disciplines

Publication Date

October 17, 2017

DOI

10.18632/oncotarget.21262

Citation Information

Zeus A. Antonello, Nancy Hsu, Manoj Bhasin, Giovanni Roti, et al.. "Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF V600E" Oncotarget Vol. 8 Iss. 49 (2017) p. 84743 - 84760
Available at: http://works.bepress.com/zeus-antonello/1/